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Purpose: Cell transplantation of myelin-producing exogenous cells is being exten-
sively explored as a means of remyelinating axons in X-linked adrenoleukodystro-
phy. We determined whether 3,3’,5-Triiodo-L-thyronine (T3) overexpresses the 
ABCD2 gene in the polysialylated (PSA) form of neural cell adhesion molecule 
(NCAM)-positive cells and promotes cell proliferation and favors oligodendrocyte 
lineage differentiation. Materials and Methods: PSA-NCAM+ cells from new-
born Sprague-Dawley rats were grown for five days on uncoated dishes in defined 
medium with or without supplementation of basic fibroblast growth factor (bFGF) 
and/or T3. Then, PSA-NCAM+ spheres were prepared in single cells and trans-
ferred to polyornithine/fibronectin-coated glass coverslips for five days to deter-
mine the fate of the cells according to the supplementation of these molecules. T3 
responsiveness of ABCD2 was analyzed using real-time quantitative polymerase 
chain reaction, the growth and fate of cells were determined using 5-bromo-2-de-
oxyuridine incorporation and immunocytochemistry, respectively. Results: Re-
sults demonstrated that T3 induces overexpression of the ABCD2 gene in PSA-
NCAM+ cells, and can enhance PSA-NCAM+ cell growth in the presence of 
bFGF, favoring an oligodendrocyte fate. Conclusion: These results may provide 
new insights into investigation of PSA-NCAM+ cells for therapeutic application to 
X-linked adrenoleukodystrophy.
Key Words:   X-linked adrenoleukodystrophy, polysialylated form of the neural cell 
adhesion molecule cells, 3,3’,5-Triiodo-L-thyronine, ABCD2 gene
INTRODUCTION
X-linked adrenoleukodystrophy (ALD), a fatal neurodegenerative disorder, is 
caused by a defect in the ATP-binding Cassette Sub-family D Member 1 (ABCD1) 
gene, which is involved in the peroxisomal oxidation of very long chain fatty acids 
(VLCFAs).1 
Inflammatory demyelination is known to be a predominant pathological change 
in X-ALD. Currently, the therapeutic options of ALD patients are extremely limit-
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Isolation and culture of PSA-NCAM+ pre-progenitors
PSA-NCAM+ pre-progenitors were obtained by a Percoll 
density gradient using a slight modification of the isolation 
procedure described by Lubetzki and co-workers (Fig. 1A).6,9 
In brief, the Sprague-Dawley newborn rats were sacrificed 
by decapitation and their brains were prepared after olfactory 
bulbs, cerebellum, and brainstem were removed. The brains 
that were minced in Hanks’ medium (18 mM sodium bicar-
bonate) were enzymatically digested with 0.1% trypsin/
EDTA during 15 minutes at 37°C and digestion was stopped 
by fetal bovine serum. The tissue was filtered using nylon 
meshes with 70 and 40 μm pores. Dissociated cells were lay-
ered on a Percoll density gradient consisting of 4.8 mL of 
90% Percoll in 0.15 M NaCl, and 7.2 mL of 1X HBSS, and 
centrifuged at 23500 g for 45 minutes at 4°C. The fraction 
was collected and washed twice in Hanks’ medium. The pel-
let, was resuspended in DMEM/F12 supplemented with 
B27, 25 mg/mL of bovine insulin, 100 mg/mL of transferrin, 
20 nM progesterone, 100 μM putrescin, 30 nM sodium sele-
nite, and 10 ng/mL of bFGF. The cell suspension was plated 
on culture plates (35-mm dishes) coated with 5% bovine se-
rum albuminutes (BSA) at 3.0×105 cells/cm2 (3 mL of medi-
um/dish). The effects of the following factors were evaluat-
ed, either alone or in combination: bFGF (10 ng/mL) and T3 
(40 ng/mL). PSA-NCAM+ spheres that had been grown for 
five days on uncoated dishes in defined medium were pre-
pared into single cells via trypsination and transferred to 
polyornithine/fibronectin-coated glass coverslips at low den-
sity for 3-5 days to determine the fate of cells derived from 
individual spheres. At that time, bFGF was omitted from the 
medium to allow differentiation. At days in vitro (DIV) 3 and 
DIV 7, spheres were also seeded onto coverslips in 100 μL 
droplets for 30 minutes, fixed with 4% paraformaldehyde in 
phosphate-buffered saline (PBS) for 10 minutes and rinsed 
with PBS to characterize the spheres (Fig. 1B).
Immunocytochemistry
Cells was stained with the following primary antibodies: 
monoclonal antibodies against PSA-NCAM (IgM, 1/200 
dilution; Millipore, Billerica, MA, USA), nestin (IgG1, 
1/50 dilution; BD INC., Franklin Lakes, NJ, USA), O4 
(IgM, 1 : 500 dilution; R&D Systems, Minneapolis, MN, 
USA), GFAP (rabbit antibody, IgG, 1/500 dilution; Co-
vance Research Products Princeton, NJ, USA), and βIII tu-
bulin (IgG2a, 1 : 500 dilution; Dako Cytomation, Carpinte-
ria, CA, USA). The following secondary antibodies were 
used at a 1/200 dilution (all obtained from Molecular 
ed.1 Dietary therapy with Lorenzo’s oil found to reduce the 
VLCFA levels in plasma but not in the brain and does not 
retard the progressive demyelination. To date, there are no 
suitable therapeutic drugs available that can cure X-ALD 
either. Although allogeneic hematopoietic stem cell trans-
plantation is the only effective therapy for childhood cere-
bral adrenoleukodystrophy, limitations by HLA-matched 
donors, a considerable risk of mortality, and a narrow thera-
peutic window remain to be resolved. More recently, clini-
cal trial of genetically corrected autologous hematopoietic 
stem cells in ALD patients was conducted.2 However, af-
fected cerebral lesions are barely recovered and their long 
term efficacy needs to be proven.
Cell transplantation of myelin-producing exogenous cells 
is being extensively explored as a means of replacing the 
genetically dysfunctional cells.3 Precursors of oligodendro-
cyte (OD) progenitors express the polysialylated (PSA) 
form of the neural cell adhesion molecule (NCAM) and 
these PSA-NCAM+ cells are useful for transplantation stud-
ies because of their high motility, rapid proliferation and de-
fault differentiation to glial cells within the brain.4,5 In ro-
dents, 3,3’,5-triiodo-L-thyronine (T3) can enhance PSA-
NCAM+ cell growth in the presence of basic fibroblast 
growth factor (bFGF), favoring an OD fate.6 In addition, T3 
is suggested to induce the ABCD2 redundant gene which is 
functionally related to ABCD1 gene and can correct the 
biochemical defect in the ABCD1 knockout mouse.7,8
Here, we determined if the emergence of PSA-NCAM at 
the surface of neonatal rat brain precursors coincides with 
their restriction to a mostly glial fate. T3 modulates these 
events by enhancing PSA-NCAM+ cell growth in bFGF 
and favoring an OD fate. We investigated the regulation of 
ABCD2 gene expression in PSA-NCAM+ cells upon T3 
treatment. 
MATERIALS AND METHODS
　　　
Newborn Sprague-Dawley rat pups were obtained from 
Charles River Laboratories (Wilmington, MA, USA). 
DMEM/F12 and B27 purchased from Invitrogen (Grand 
Island, NY, USA). Percoll was obtained from Pharmacia 
(Uppsala, Sweden). All other products were purchased 
from Sig ma Chemicals (St. Louis, MO, USA) if not speci-
fied otherwise. The protocol used in this study was ap-
proved by the Yonsei University Animal Use Committee 
and by the IRB for animal research.
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were cultured for 16 hours in growth media containing 10 
µM BrdU and then fixed in 5% glacial acetic acid, 95% 
ethanol for 5-10 minutes. Subsequently, the cells were incu-
bated in 2N HCl for 10 minutes to denature DNA, and 
washed twice in 0.1N sodium borate (pH 8.5) for 10 min-
utes to neutralize the acid. After 3 washes with PBS, cells 
were incubated with anti-BrdU antibody (1 : 50 dilution), 
followed by incubation with a fluorescein conjugated goat 
anti-mouse IgG antibody (1 : 100 dilution) for 30 minutes, 
washed three times, counterstained with 1 mg/mL propidi-
um iodide in 0.1% sodium citrate buffer for 10 minutes and 
visualized by confocal microscopy for cell counting.
When BrdU labeling was combined with surface label-
ing, cells were first fixed in 4% formaldehyde and incubat-
ed with PSA-NCAM antibody (dilution 1 : 250) for 45 
minutes, followed by washing and incubation with rhoda-
minutese-conjugated anti-mouse IgM (dilution 1 : 100).6 
The clusters were then post-fixed with acid-alcohol and 
processed for BrdU labeling as described above.
Reverse transcription polymerase chain reaction 
(RT-PCR)
Total RNA of PSA-NCAM+ spheres at DIV5 was prepared 
Probes, Grand Island, NY, USA): Alexa Fluor 488 donkey 
anti-mouse IgG, Alexa Fluor 488 chicken anti-mouse IgG, 
Alexa Fluor 594 chicken anti-mouse IgG, Alexa Fluor 594 
chicken anti-rabbit IgG, and tetramethylrhodamine isothiocy-
anate-conjugated goat anti mouse IgM. Both primary and 
secondary antibodies were diluted in 0.1% BSA containing 
10% normal goat serum (NGS). Cells were saturated with 
0.1% BSA containing 10% NGS and incubated with the pri-
mary antibody for one hour at room temperature. After rins-
ing with 0.1% BSA, the appropriate secondary antibodies 
were used, and then rinsed again with 0.1% BSA. Finally, 
they were rinsed and stained with Fluoromount-G including 
0.1 μg/mL 4’,6-diamidine-2’-phenylindole dihydrochloride 
(DAPI) (Vector Laboratories, Burlingame, CA, USA). The 
percentage of the various cell types was counted by the 
number of immunoreactive cells for each marker/the total 
number of DAPI+ cells.
BrdU assay
The incorporation of 5-bromo-2-deoxyuridine (BrdU) (BD 
pharmingen, San Diego, CA, USA) was quantified by 
FACS for cell proliferation assay according to manufactur-
er’ prosedure. In brief, the cells at DIV1, DIV2 and DIV3 
Fig. 1. (A) From neonatal Sprague Dawley rat brain, abundant PSA-NCAM+ cells were isolated by Percoll density gradient method. (B) 
The culture and differentiation protocol for PSA-NCAM+ cells. (C) Progenitor cells identified using the nestin and PSA-NCAM markers. 
Scale bar=50 μm. PSA, polysialylated; NCAM, neural cell adhesion molecule; DAPI, 4’,6-diamidine-2’-phenylindole dihydrochloride; T3, 
3,3’,5-Triiodo-L-thyronine; bFGF, basic fibroblast growth factor.
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the effect of T3 on PSA-NCAM+ cell proliferation in re-
sponse to bFGF, BrdU incorporation assay was performed 
between three and four days. 
In the absence of T3 and bFGF, 2% of all cells were in 
DNA synthesis after three days in vitro. T3 alone did not sig-
nificantly alter cell proliferation. The survival rate was 6.5-
fold higher cells than in the untreated controls when only 
bFGF was added to the culture medium. In cultures treated 
with both bFGF and T3,  however, survival rate was 9.5-fold 
higher than that of the untreated controls (p<0.01) and 1.5-
fold higher than the cells treated with bFGF alone (p<0.05) 
(Fig. 3), suggesting that T3 could increase the proliferative 
response of PSA-NCAM+ cells only in the presence of bFGF 
(Fig. 3). 
The fate of PSA-NCAM+ cells is dependent on thyroid 
hormone 
We next examined the differentiation potentials of PSA-
NCAM+ cells after adhesion. All clusters/spheres were cul-
with the RNeasy Kit (Qiagen, Valencia, CA, USA). For re-
verse transcription, 1 µg of RNA was transcribed into 
cDNA using Superscript II reverse transcriptase (Invitro-
gen, Grand Island, NY, USA) according to manufacturer’ 
instructions. PCR reaction was performed with Emeral-
dAmp GT PCR Master Mix (Takara Bio Inc., Otsu, Shiga, 
Japan) using specific primers as previously reported.6
Statistical analysis 
Data were analyzed using the Student’s t-test. In addition, 
one-way analysis of variance (ANOVA) and repeated mea-
sures ANOVA were used to assess the statistical signifi-
cance of differences. 
 
RESULTS
 
The isolation and characterization of  PSA-NACM+ cells
After the isolation process as described above, we were able 
to isolate a high purity of PSA-NACM+ cells (1-1.5×107 
cells per 10 newborn rat brains). These cells, round mor-
phologically, were identified by the nestin and PSA-NCAM 
markers. In response to bFGF, PSA-NCAM+ cells grew 
and aggregated gradually to form larger clusters on uncoat-
ed tissue culture dishes (Fig. 1C). Unfortunately, there is 
still no method of keeping PSA-NCAM+ cells for a long 
time. From the isolated PSA-NCAM+ cells, PSA disap-
peared completely in 7 days. In other words, these cells 
should be transplanted within six days (Fig. 2).
Effect of thyroid hormone on PSA-NACM+ cell growth 
The combination of bFGF plus T3 produced a maximal in-
crease in cell proliferation, whereas either one of the factors 
alone showed considerably low level of growth. To examine 
Fig. 2. In the PSA-NCAM+ cells, PSA disappeared in 7 days. Scale bar 50 μm. DIV, days in vitro. PSA, polysialylated; NCAM, neural cell adhesion molecule; 
DAPI, 4’,6-diamidine-2’-phenylindole dihydrochloride.
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Fig. 3. BrdU labeling shows that  survival in cultures treated with both FGF2 
and T3 was 9.5-fold higher than in the untreated controls (p=0.0075), T3 
alone (p=0.0062) and 1.5-fold higher than cells treated with FGF2 alone 
(p=0.0433). *p<0.05; †p<0.01. BrdU, 5-bromo-2-deoxyuridine; T3, 3,3’,5- 
Triiodo-L-thyronine; bFGF, basic fibroblast growth factor.
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with FGF2 and T3. These cells were differentiated into as-
trocytes (51%) and oligodendrocytes (44%), while only 5% 
neurons were observed. In the absence of T3 and FGF2 or 
with T3 only, only 20% oligodendrocytes were observed 
(p<0.01). In cultures treated with FGF2 only, 31% oligo-
dendrocytes were observed (p<0.05) (Fig. 4).
Taken together, these results suggest that, T3 and bFGF 
may induce proliferation and promote an oligodendrocyte 
fate in these PSA-NCAM+ cells under our experimental 
conditions.
T3 Induces ABCD2 expression in PSA-NCAM+ cells
To determine whether our in vitro findings have physiologi-
cal relevance, we studied the in vivo effects of T3 on 
ABCD2 expression in the PSA-NCAM+ cells, a major target 
of T3,8 and which can be transplanted for an X-ALD thera-
py. We observed induction of the gene in the PSA-NCAM+ 
cells, at the 40 ng/mL T3 and 10 ng/mL FGF2 dose, 1.8-fold 
higher than in untreated controls (p<0.05) and 1.7-fold high-
er than cells treated with FGF2 alone (p<0.05) (Fig. 5).
DISCUSSION
Herein, we determined whether the emergence of PSA-
NCAM in vitro at the surface of neonatal rat brain precur-
tured under conditions with growth factors for five days 
and then transferred onto a dish or coverslip coated with 
polyornithine in the same medium without growth factors. 
Within a few hours, the cells migrated out of the clusters/
spheres and grew processes, often showing a bipolar shape. 
After five days, many differentiated cells in the outgrowth 
were stained with O4 (oligodendrocytes), GFAP (astro-
cytes), and Tuj1 (neurons) antibodies. The great majority of 
pre-progenitor clusters showed GFAP+ plus O4+ cells. We 
then tested the fate of PSA-NCAM+ cell spheres grown 
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Fig. 4. (A) Oligodendrocytes identified using the O4 marker. (B) In PSA-NCAM+ cell, spheres grown with FGF2 and T3 differentiated into as-
trocytes (51%) and oligodendrocytes (44%), while only 5% neurons were observed. In the absence of T3 and FGF2 or with T3 only, only 
20% oligodendrocytes were observed (p=0.0023), whereas 31% oligodendrocytes were observed in cultures treated with FGF2 only 
(p=0.035). Scale bar=50 μm. *p<0.05; †p<0.01. T3, 3,3’,5-Triiodo-L-thyronine; bFGF, basic fibroblast growth factor; PSA, polysialylated; 
NCAM, neural cell adhesion molecule.
Fig. 5. The value of real-time quantitative polymerase chain reaction at the 
40 ng/mL T3 and 10 ng/mL FGF2 dose. The induction of the ABCD2 gene in 
the PSA-NCAM+ cells was, 1.8-fold higher than in untreated controls 
(p=0.0325) and 1.7-fold higher than cells treated with FGF2 alone (p=0.0345). 
*p<0.05. T3, 3,3’,5-Triiodo-L-thyronine; bFGF, basic fibroblast growth factor; 
PSA, polysialylated; NCAM, neural cell adhesion molecule.
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of multiple sclerosis. Accumulation of cholesterol ester 
causes an inflammatory response.10 A study of the regula-
tion of ABCD2 expression in PSA-NCAM+ cells would be 
of great interest because these cells can survive efficiently 
in X-ALD brain. In the present study, we confirmed that T3 
also induces an overexpression of the ABCD2 gene in the 
PSA-NCAM+ cells.
X-ALD may be an example of a neurological disorder 
where new therapeutic strategies, such as gene modified 
cell therapy, will be required. PSA-NCAM+ cells, over-ex-
pressing ALDRP in high yield and high purity, are expected 
to extensively remyelinate CNS axons and efficiently sur-
vive in the X-ALD brain. Thus, the results described herein 
may provide new insights into investigating PSA-NCAM+ 
cells derived from human neural precursors for therapeutic 
application.
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